303 related articles for article (PubMed ID: 31147790)
1. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.
Tao L; Zhou J; Yuan C; Zhang L; Li D; Si D; Xiu D; Zhong L
Metabolomics; 2019 May; 15(6):86. PubMed ID: 31147790
[TBL] [Abstract][Full Text] [Related]
2. High-Performance Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry for Exosome Metabolomics.
Luo X; An M; Cuneo KC; Lubman DM; Li L
Anal Chem; 2018 Jul; 90(14):8314-8319. PubMed ID: 29920066
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
Luo X; Liu J; Wang H; Lu H
Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
[TBL] [Abstract][Full Text] [Related]
4. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
5. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
6. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.
Madhavan B; Yue S; Galli U; Rana S; Gross W; Müller M; Giese NA; Kalthoff H; Becker T; Büchler MW; Zöller M
Int J Cancer; 2015 Jun; 136(11):2616-27. PubMed ID: 25388097
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
8. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
[TBL] [Abstract][Full Text] [Related]
9. Size Dependent Lipidomic Analysis of Urinary Exosomes from Patients with Prostate Cancer by Flow Field-Flow Fractionation and Nanoflow Liquid Chromatography-Tandem Mass Spectrometry.
Yang JS; Lee JC; Byeon SK; Rha KH; Moon MH
Anal Chem; 2017 Feb; 89(4):2488-2496. PubMed ID: 28192938
[TBL] [Abstract][Full Text] [Related]
10. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer.
Cheng F; Wen Z; Feng X; Wang X; Chen Y
Life Sci; 2020 Nov; 260():118489. PubMed ID: 32976882
[TBL] [Abstract][Full Text] [Related]
11. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
[TBL] [Abstract][Full Text] [Related]
12. Characterization and proteomic profiling of pancreatic cancer-derived serum exosomes.
Jiao YJ; Jin DD; Jiang F; Liu JX; Qu LS; Ni WK; Liu ZX; Lu CH; Ni RZ; Zhu J; Xiao MB
J Cell Biochem; 2019 Jan; 120(1):988-999. PubMed ID: 30160795
[TBL] [Abstract][Full Text] [Related]
13. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
14. Upregulated exosomic miR‑23b‑3p plays regulatory roles in the progression of pancreatic cancer.
Chen D; Wu X; Xia M; Wu F; Ding J; Jiao Y; Zhan Q; An F
Oncol Rep; 2017 Oct; 38(4):2182-2188. PubMed ID: 28849236
[TBL] [Abstract][Full Text] [Related]
15. Progress and potential of exosome analysis for early pancreatic cancer detection.
Erb U; Zöller M
Expert Rev Mol Diagn; 2016 Jul; 16(7):757-67. PubMed ID: 27206554
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipidomics reveals potential lipid markers of major depressive disorder.
Liu X; Li J; Zheng P; Zhao X; Zhou C; Hu C; Hou X; Wang H; Xie P; Xu G
Anal Bioanal Chem; 2016 Sep; 408(23):6497-507. PubMed ID: 27457104
[TBL] [Abstract][Full Text] [Related]
17. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.
Liu X; Zheng W; Wang W; Shen H; Liu L; Lou W; Wang X; Yang P
Br J Cancer; 2017 Dec; 117(12):1846-1854. PubMed ID: 29123261
[TBL] [Abstract][Full Text] [Related]
18. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
[TBL] [Abstract][Full Text] [Related]
19. RNA-Binding Motif Protein 6 is a Candidate Serum Biomarker for Pancreatic Cancer.
Duan B; Hu X; Fan M; Xiong X; Han L; Wang Z; Tong D; Liu L; Wang X; Li W; Yang J; Huang C
Proteomics Clin Appl; 2019 Sep; 13(5):e1900048. PubMed ID: 31207145
[TBL] [Abstract][Full Text] [Related]
20. High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
Wang M; Guo S; He M; Shao X; Feng L; Yu Y; Gong W; Liu Q; Melnikov V; Wang X; He Z; Jiang L; Chen M; Sun J; Cai J; Zhao Y; Li Y; Tritos NA; Hu Z; Zhang Z
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31930294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
